Varex Imaging Corp. (VREX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$18.51-0.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · VREX
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $19 VREX trades at 17× p/e, below its 28× p/e peer median. Our $20 fair value sits above the price. It's a high-confidence read. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| graham number | 12M | $17.06 | — | — | TTM | high |
| Peer P/E | 12M | $30.53 | 28.3 | 1.08 | TTM | high |
| Peer P/S | 12M | $58.36 | 2.9 | 19.83 | TTM | high |
| residual income | 12M | $12.09 | — | — | TTM | high |
| Own P/E history | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $0.36/sh owner earnings.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
| $12.43 |
| 11.5 |
| 1.08 |
| TTM |
| high |
| triangulated | 12M | $33.22 | 28.3 | 1.18 | Triangulated | high |
| Peer P/S | 3Y | $65.75 | 2.9 | 22.34 | guidance | medium |
| Peer P/S | 5Y | $69.76 | 2.9 | 23.70 | guidance | medium |